Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harold Bays

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
European Journal of Preventive Cardiology|August 25, 2022
Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity FederationFrancisco Lopez-Jimenez, Wael Almahmeed, Harold Bays, et al.
Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery|April 7, 2016
Lipids and bariatric procedures Part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA)Harold Bays, Shanu N Kothari, Dan E Azagury, et al.
Journal of the American College of Cardiology|February 11, 2014
Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trialsFrederick J Raal, Robert P Giugliano, Marc S Sabatine, et al.
Journal of Clinical Lipidology|March 29, 2022
Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trialsUlrich Laufs, Christie M Ballantyne, Maciej Banach, et al.
Diabetes, Obesity & Metabolism|April 1, 2024
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label studyElena A Christofides, Orlando Puente, Paul Norwood, et al.
Clinical Cardiology|January 24, 2003
Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemiaJonathan Isaacsohn, Donald Hunninghake, Helmut Schrott, et al.
Cell Metabolism|October 3, 2006
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adultsNgozi Erondu, Ira Gantz, Bret Musser, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
European Journal of Preventive Cardiology|August 25, 2022
Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity FederationFrancisco Lopez-Jimenez, Wael Almahmeed, Harold Bays, et al.
Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery|April 7, 2016
Lipids and bariatric procedures Part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA)Harold Bays, Shanu N Kothari, Dan E Azagury, et al.
Journal of the American College of Cardiology|February 11, 2014
Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trialsFrederick J Raal, Robert P Giugliano, Marc S Sabatine, et al.
Journal of Clinical Lipidology|March 29, 2022
Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trialsUlrich Laufs, Christie M Ballantyne, Maciej Banach, et al.
Diabetes, Obesity & Metabolism|April 1, 2024
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label studyElena A Christofides, Orlando Puente, Paul Norwood, et al.
Clinical Cardiology|January 24, 2003
Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemiaJonathan Isaacsohn, Donald Hunninghake, Helmut Schrott, et al.
Cell Metabolism|October 3, 2006
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adultsNgozi Erondu, Ira Gantz, Bret Musser, et al.
Pageof 8